title: The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series.
abstract: Tiagabine is currently approved by the Food and Drug Administration for use in treating certain forms of epilepsy. Like other anticonvulsant agents, tiagabine has been explored for use as a mood stabilizer and in panic disorder. This article presents a case series of five patients who were prescribed tiagabine for treatment-resistant anxiety.
authors.affiliation: Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA. thomas_Schwartz@yahoo.com
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Schwartz
mesh_terms: D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009557:Nipecotic Acids / Q000627:therapeutic use*; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy; D000078308:Tiagabine
chemical_list: D014151:Anti-Anxiety Agents; D018696:Neuroprotective Agents; D009557:Nipecotic Acids; D000078308:Tiagabine